Report on research findings announced at meeting in May 2002.

Manufacturer's site for this selective serotonin and norepinephrine reuptake inhibitor (SSNRI), approved in the US to treat diabetic peripheral neuropathic pain and major depression.

Full prescribing information from RxList.

Report on study findings announced in October 2002. [MedScape - Free registration required.]

Abstract of study findings published in April 2002.

News on FDA action in September 2002 related to the dual 5HT/noradrenaline reuptake inhibitor (also known as Cymbalta) for the treatment of depression.

News article reports that duloxetine appears promising as a treatment for stress urinary incontinence. July 2002.